The DOI matches its Crossref record; 27 of the 32 references it cites were found in a registry or an index.
Vibration-Controlled Transient Elastography Scores to Predict Liver-Related Events in Steatotic Liver Disease
Open accessAbstract
Importance: Metabolic dysfunction-associated steatotic liver disease (MASLD) is currently the most common chronic liver disease worldwide. It is important to develop noninvasive tests to assess the disease severity and prognosis. Objective: To study the prognostic implications of baseline levels and dynamic changes of the vibration-controlled transient elastography (VCTE)-based scores developed for the diagnosis of advanced fibrosis (Agile 3+) and cirrhosis (Agile 4) in patients with MASLD. Design, Setting, and Participants: This cohort study included data from a natural history cohort of patients with MASLD who underwent VCTE examination at 16 tertiary referral centers in the US, Europe, and Asia from February 2004 to January 2023, of which the data were collected prospectively at 14 centers. Eligible patients were adults aged at least 18 years with hepatic steatosis diagnosed by histologic methods (steatosis in ≥5% of hepatocytes) or imaging studies (ultrasonography, computed tomography or magnetic resonance imaging, or controlled attenuation parameter ≥248 dB/m by VCTE). Main Outcomes and Measures: The primary outcome was liver-related events (LREs), defined as hepatocellular carcinoma or hepatic decompensation (ascites, variceal hemorrhage, hepatic encephalopathy, or hepatorenal syndrome), liver transplant, and liver-related deaths. The Agile scores were compared with histologic and 8 other noninvasive tests. Results: A total of 16 603 patients underwent VCTE examination at baseline (mean [SD] age, 52.5 [13.7] years; 9600 [57.8%] were male). At a median follow-up of 51.7 (IQR, 25.2-85.2) months, 316 patients (1.9%) developed LREs. Both Agile 3+ and Agile 4 scores classified fewer patients between the low and high cutoffs than most fibrosis scores and achieved the highest discriminatory power in predicting LREs (integrated area under the time-dependent receiver-operating characteristic curve, 0.89). A total of 10 920 patients (65.8%) had repeated VCTE examination at a median interval of 15 (IQR, 11.3-27.7) months and were included in the serial analysis. A total of 81.9% of patients (7208 of 8810) had stable Agile 3+ scores and 92.6% of patients (8163 of 8810) had stable Agile 4 scores (same risk categories at both assessments). The incidence of LREs was 0.6 per 1000 person-years in patients with persistently low Agile 3+ scores and 30.1 per 1000 person-years in patients with persistently high Agile 3+ scores. In patients with high Agile 3+ score at baseline, a decrease in the score by more than 20% was associated with substantial reduction in the risk of LREs. A similar trend was observed for the Agile 4 score, although it missed more LREs in the low-risk group. Conclusions and Relevance: Findings of this study suggest that single or serial Agile scores are highly accurate in predicting LREs in patients with MASLD, making them suitable alternatives to liver biopsy in routine clinical practice and in phase 2b and 3 clinical trials for steatohepatitis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In longitudinal studies with serial VCTE measurements, changes in LSM (20% increase, stable, 20% decrease) correlated with the risk of liver-related events (including HCC) and liver-related death. 184,185”
From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [184]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Several observational studies showed that LSM had good accuracy for liver-related events, liver-related and overall mortality. 178,183,184”
From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [184]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Baveno VII – Renewing consensus in portal hypertension
de Franchis, R., Bosch, J., Garcia-Tsao, G., Reiberger, T., Ripoll, C., Abraldes, J. G., Albillos, A., Baiges, A., Bajaj, J., Bañares, R., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2021.12.022 · Cited by 2,930
Self-citationNon-alcoholic fatty liver disease
Powell, E. E., Wong, V. W.-S., & Rinella, M. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32511-3 · Cited by 2,789
Self-citationTaylor, R. S., Taylor, R. J., Bayliss, S., Hagström, H., Nasr, P., Schattenberg, J. M., Ishigami, M., Toyoda, H., Wai-Sun Wong, V., Peleg, N., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.01.043 · Cited by 1,069
Self-citationHagström, H., Nasr, P., Ekstedt, M., Hammar, U., Stål, P., Hultcrantz, R., & Kechagias, S. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.07.027 · Cited by 1,067
Self-citationAge as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis
McPherson, S., Hardy, T., Dufour, J.-F., Petta, S., Romero-Gomez, M., Allison, M., Oliveira, C. P., Francque, S., Van Gaal, L., Schattenberg, J. M., et al. (2017) · American Journal of Gastroenterology · doi:10.1038/ajg.2016.453 · Cited by 945
Self-citationNewsome, P. N., Sasso, M., Deeks, J. J., Paredes, A. H., Boursier, J., Chan, W., Yilmaz, Y. N., Czernichow, S., Zheng, M., Wong, V. W., et al. (2020) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(19)30383-8 · Cited by 839
Self-citationChanging epidemiology, global trends and implications for outcomes of NAFLD
Wong, V. W.-S., Ekstedt, M., Wong, G. L.-H., & Hagström, H. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.04.036 · Cited by 765
Self-citationMittal, S., El-Serag, H. B., Sada, Y. H., Kanwal, F., Duan, Z., Temple, S., May, S. B., Kramer, J. R., Richardson, P. A., & Davila, J. A. (2016) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2015.07.019 · Cited by 648
Noninvasive biomarkers in NAFLD and NASH — current progress and future promise
Wong, V. W., Adams, L. A., de Lédinghen, V., Wong, G. L., & Sookoian, S. C. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0014-9 · Cited by 617
Self-citation
Research works printed but not linked: 5
- Blanche, 2013, Estimating and comparing time-dependent areas under receiver operating characteristic curves for censored event times with competing risks., Stat Med, 32, 5381, 10.1002/sim.5958 · DOI
- Yuan, 2018, A threshold-free summary index of prediction accuracy for censored time to event data., Stat Med, 37, 1671, 10.1002/sim.7606 · DOI
- Pencina, 2011, Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers., Stat Med, 30, 11, 10.1002/sim.4085 · DOI
- Uno, 2013, A unified inference procedure for a class of measures to assess improvement in risk prediction systems with survival data., Stat Med, 32, 2430, 10.1002/sim.5647 · DOI
- Chow, 2019, Repeating measurements by transient elastography in non-alcoholic fatty liver disease patients with high liver stiffness., J Gastroenterol Hepatol, 34, 241, 10.1111/jgh.14311 · DOI · Paper page
Cited by
Sorted by citations
Items 201–251 of 251
Soft drink consumption and liver fibrosis in type 2 diabetes
Ferro, A., Bollati, M., Caviglia, G. P., Armandi, A., Bellini, S., Limoncelli, S., Mengozzi, G., Barutta, F., Broglio, F., Beccuti, G., et al. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1726040
Self-citationSinghai, A., Meena, R., Joshi, R. P., Khadanga, S., & Jhaj, R. (2026) · Cureus · doi:10.7759/cureus.101710
Clinical utility of the MAF-5 score for assessing MAFLD/MASLD in a Japanese population with obesity
Fukumitsu, H., Sakaguchi, K., Nishisaka, M., Katsura, Y., Morita, Y., Otowa‐Suematsu, N., Yamada, T., Yano, Y., Takahashi, M., Asahara, S.-I., et al. (2026) · Diabetology International · doi:10.1007/s13340-025-00874-2
Cheung, J. T. K., Zhang, X., Wong, G. L., Yip, T. C., Lin, H., Li, G., Leung, H. H. W., Lai, J. C., Mahadeva, S., Mustapha, N. R. N., et al. (2026) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2026.01.035
Self-citationNoninvasive Testing for Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
Kalligeros, M., Castéra, L., Tsochatzis, E. A., & Alkhouri, N. (2026) · Clinics in Liver Disease · doi:10.1016/j.cld.2025.12.004
Self-citationYu, H., Li, M., Wu, B., & Yang, Y. (2026) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.70283
Han, W. M., Apornpong, T., Chuaypen, N., Aung, T. P. P., Amornritvanich, P., Hiranburana, N., Lwin, H. M. S., Hiransuthikul, A., Kerr, S. J., Tangkijvanich, P., et al. (2026) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkag053
Algorithms for Risk Stratification in Patients with Metabolic Dysfunction-Associated Steatohepatitis
Armandi, A., Bugianesi, E., Loomba, R. S., & Caussy, C. (2026) · Clinics in Liver Disease · doi:10.1016/j.cld.2025.12.005
Self-citationPrimary Biliary Cholangitis—The Changing Biomarker Paradigms for Staging Fibrosis
Moyana, T. N. (2026) · Livers · doi:10.3390/livers6020023
Dong, B., Chen, Y., & Qi, X. (2026) · Gut · doi:10.1136/gutjnl-2026-338610
Rationale Diagnostik bei metabolischen Lebererkrankungen (MASLD)
Barton, A., & Schattenberg, J. M. (2026) · Die Diabetologie · doi:10.1007/s11428-026-01456-9
Serenari, M., Cescon, M., Bonatti, C., Stefanini, B., Prosperi, E., Dajti, E., Tovoli, F., Ravaioli, M., Piscaglia, F., & Ravaioli, F. (2026) · JHEP Reports · doi:10.1016/j.jhepr.2026.101825
Swerkersson, S., Bartholomä, W. C., Forsgren, M. F., Stjernman, H., Sjögren, D., Kechagias, S., Nasr, P., Holmberg, M., Lundberg, P., Rejler, M., et al. (2026) · European Journal of Radiology · doi:10.1016/j.ejrad.2026.112845
Pham, A. G., Le, A. V.-K., Pham, Y. T., Nguyen, L. S., Nguyen, H. L., Quach, N., Cao, T. M., Nguyen, H. T., Thai, X. T., Luong, A. T., et al. (2026) · Scientific Reports · doi:10.1038/s41598-026-45659-y
EUS point shear-wave elastography: A novel approach for noninvasive liver fibrosis assessment
Miutescu, B. P., Burdan, A., Gadour, E., Facciorusso, A., Alqahtani, M., Rațiu, I., Nica, C., Ghiuchici, A. M., Danilă, M., Șirli, R., et al. (2026) · Endoscopic Ultrasound · doi:10.1097/eus.0000000000000195
Application and interpretation of non-invasive testing in MetALD
Chan, W., Liu, K., Goh, G. B., & Wong, V. W. (2026) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2026.30
Self-citationYu, Q., Lin, Y.-Y., Gui, Z.-H., Duan, H.-L., Yang, J.-J., Meng, Y., Peng, X.-T., Lan, L., Wan, H., & Shen, J. (2026) · World Journal of Gastroenterology · doi:10.3748/wjg.v32.i21.118057
Renal elastography in kidney disease: Current evidence, limitations, and future directions
Mora-Loján, J. L., García-Trujillo, O. F., Vélez-Hurtado, G., Bermúdez-Mercado, E., Pacheco-Salazar, F., Balderas-Juarez, J., & Martínez‐Sánchez, F. D. (2026) · World Journal of Nephrology · doi:10.5527/wjn.119841
Cai, K., Lin, Z. T., Zhang, X.-M., Yu, J., Cui, T.-J., Zhang, Y., Zou, R.-H., Zheng, Z., Zhou, Y., Zhu, T., et al. (2026) · Microbial Pathogenesis · doi:10.1016/j.micpath.2026.108634
Fouad, Y. M., AlNaamani, K. M., Alawadi, F., Hassani, A. A., Alkhalidi, N. M. F., Hotayt, B., Abaalkhail, F. A., Rouabhia, S., Abdulla, M., Altarrah, M. Y., et al. (2026) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2026.2698115
He, X.-L., Yang, R.-X., & Fan, J.-G. (2026) · Hepatoma Research · doi:10.20517/2394-5079.2026.32
Self-citationLee, J., Yang, H., Bae, S. H., Yoo, S. H., Nam, S. W., Yoon, J., Kwon, J. H., & Lee, S. K. (2026) · JHEP Reports · doi:10.1016/j.jhepr.2026.101963
Wang, X. W., Dong, X., 钱洛丹, Yang, Z., Yang, D., & Niu, Y. (2026) · Academic Radiology · doi:10.1016/j.acra.2026.06.068
Lefere, S., Putri, R. R., Danielsson, P., Casswall, T., Marcus, C., Hudert, C. A., Geerts, A. M., Bruyne, R. D., & Hagman, E. (2026) · Diabetologia · doi:10.1007/s00125-026-06804-4
Soloveva, A. E., Park, J. J., Apostolou, E., Böhm, M., Cannata, A. N., Fudim, M., Kittipibul, V., Mueller, S., Potapova, K., Schattenberg, J. M., et al. (2026) · European Journal of Heart Failure · doi:10.1093/ejhf/xuag243
Beltran, T., Rogers, S. M., Molina, J. N. N., Maldonado, C. J., Berry-Cabán, C. S., & Choi, Y. S. (2026) · Military Medicine · doi:10.1093/milmed/usag117
Effect of intragastric balloon on weight loss and liver elastography
Herling, A., Feiglin, S., Greener, T., Shoham, Hovel, D., Dreizin, V., Khalaila, N., Dankovich, N., Laks, S., Israeli, E., et al. (2026) · Journal of Gastrointestinal Surgery Open · doi:10.1016/j.jogsop.2026.100039
Ayoub, M., Tsutsumi, T., & Rinella, M. E. (2026) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70921 · Cited by 1
Younossi, Z. M., Papatheodoridis, G., Tsochatzis, E. A., Buti, M., Rimassa, L., Pinzani, M., Lleò, A., Shawcross, D. L., Tacke, F., Wong, V. W., et al. (2026) · Liver International · doi:10.1111/liv.70806 · Cited by 1
Self-citationDeng, Y., Xing, Z., Tan, J., Zu, J., Zhang, Y., Cui, X., Zhang, C., Fei, Q., Qu, D., Yang, Z., et al. (2026) · iLiver · doi:10.1016/j.iliver.2026.100258
Jeffrey, A. W., Tsochatzis, E. A., Genescà, J., Adams, L. A., Wallace, M. C., Jeffrey, G. P., & Majumdar, A. (2026) · Gut · doi:10.1136/gutjnl-2026-339845
Self-citationSwierczek, D., Dreger, M., Jatkowski, J., Kancerek, J., Drozdzowska, B., & Wojnicz, R. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27177825
Feng, G., 宫守平, Tacke, F., Valenti, L. V. C., Muthiah, M. D., Kato, K., Yu, Z., Targher, G., Byrne, C. D., Allam, M. F., et al. (2026) · The Lancet Primary Care · doi:10.1016/j.lanprc.2026.100205
Self-citationLiver stiffness dynamics in European populations – Authors’ reply
Pustjens, J., Ginès, P., & Brouwer, W. P. (2026) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(26)00238-4
Mironova, M., Ratziu, V., Rinella, M. E., Bansal, M. B., Noureddin, M., Alkhouri, N., Anstee, Q. M., Newsome, P. N., Schattenberg, J. M., Sanyal, A. J., et al. (2026) · Gut · doi:10.1136/gutjnl-2026-340031
Self-citationNoninvasive surrogate endpoints in MASH trials: current perspectives and challenges
Lee, H. W., Díaz, L. A., Wong, V. W., & Chan, W. (2026) · Hepatology International · doi:10.1007/s12072-026-11148-7
Self-citationNon‐Invasive Imaging Assessment of Liver Fibrosis
Navin, P. J., Welle, C. L., Pepin, K. M., Yin, M., & Venkatesh, S. K. (2026) · Journal of Medical Imaging and Radiation Oncology · doi:10.1111/1754-9485.70184
Application of artificial intelligence in hepatology
Hu, Z., Lin, Y., Gao, H., Shuai, L., Tong, Z., Nie, C., Yang, Z., & Zhao, J. (2026) · Frontiers in Digital Health · doi:10.3389/fdgth.2026.1851723
Arab, J. P., Malhi, H., Winder, G. S., & Fontana, R. J. (2026) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2026.07.027
MASLD: Established Knowledge and Emerging Directions – Guideline Updates
Roeb, E., & Geier, A. (2026) · Zeitschrift für Gastroenterologie · doi:10.1055/a-2894-7628
Ye, T., Hou, S., Lin, C., Huang, M., Huang, M., & Luo, X. (2026) · International Journal of Radiation Research · doi:10.66224/ijrr.24.3.11
EASL-EASD-EASO guidance on the use of resmetirom and semaglutide as MASH-targeted therapy
Tacke, F., Horn, P., Wong, V. W. S., Ratziu, V., Bugianesi, E., Francque, S., Zelber‐Sagi, S., Caussy, C., Roden, M., Gastaldelli, A., et al. (2026) · Journal of Hepatology · doi:10.1016/j.jhep.2026.08.028
Self-citationPredictive Runtime Verification for Clinical Event Monitoring
Lin, V., & Lee, I. (2026) · Lecture notes in computer science · doi:10.1007/978-3-032-41160-0_15
Future perspective of GLP-1 receptor agonists across the spectrum of steatotic liver disease
Gjini, K., Calleri, A., Bugianesi, E., & Armandi, A. (2026) · Hepatoma Research · doi:10.20517/2394-5079.2026.70
Self-citationSyed‐Abdul, M. M. (2026) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2026.2749643
Metabolic Dysfunction‐Associated Steatotic Liver Disease
Kanwal, F., & Wong, V. W. S. (2026) · Wiley eBooks · doi:10.1002/9781394360031.ch31
Self-citationBaveno VIII refines the continuum of advanced chronic liver disease and portal hypertension
Lai, J. C., Reiberger, T., García–Tsao, G., Berzigotti, A., & Yip, T. C. (2026) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-026-01272-y
Self-citationRatziu, V., Dufour, J., Ponnaiah, M., Pais, R., Thormann, M., Bugianesi, E., Marra, F., Boyle, M., Hallsworth, K., Aspite, S., et al. (2026) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2026.101893
Self-citationMASH Cirrhosis: A Stage‐Specific Framework for Care and Clinical Trial Design
Zhang, D. S., Tsutsumi, T., & Muthiah, M. D. (2026) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.70860
Metadata
- Authors
- Lin, H., Lee, H. W., Yip, T. C.-F., Tsochatzis, E., Petta, S., Bugianesi, E., Yoneda, M., Zheng, M.-H., Hagström, H., Boursier, J., Calleja, J. L., Goh, G. B.-B., Chan, W.-K., Gallego-Durán, R., Sanyal, A. J., de Lédinghen, V., Newsome, P. N., Fan, J.-G., Castéra, L., Lai, M., Harrison, S. A., Fournier-Poizat, C., Wong, G. L.-H., Pennisi, G., Armandi, A., Nakajima, A., Liu, W.-Y., Shang, Y., de Saint-Loup, M., Llop, E., Teh, K. K.-J., Lara-Romero, C., Asgharpour, A., Mahgoub, S., Chan, M. S.-W., Canivet, C. M., Romero-Gomez, M., Kim, S. U., Wong, V. W.-S., & VCTE-Prognosis Study Group
- Affiliations
- Chinese University of Hong Kong (HK)
- Yonsei University (KR)
- The Royal Free Hospital (GB)
- University of Palermo (IT)
- Azienda Ospedaliera Citta' della Salute e della Scienza di Torino (IT)
- Yokohama City University (JP)
- First Affiliated Hospital of Wenzhou Medical University (CN)
- Karolinska University Hospital (SE)
- Centre Hospitalier Universitaire d'Angers (FR)
- Department of Gastroenterology and Hepatology, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain
- Singapore General Hospital (SG)
- University of Malaya (MY)
- Digestive Diseases Unit and CIBERehd, Virgen Del Rocío University Hospital, Seville, Spain
- Virginia Commonwealth University (US)
- Centre d’Investigation de la Fibrose Hépatique, Haut-Lévêque Hospital, University Hospital of Bordeaux, Pessac, France
- University Hospitals Birmingham NHS Foundation Trust (GB)
- Shanghai Jiao Tong University (CN)
- Inserm (FR)
- Beth Israel Deaconess Medical Center (US)
- University of Oxford (GB)
- Echosens, Paris, France
- Karolinska Institutet (SE)
- Hepato-Gastroenterology and Digestive Oncology Department, Angers University Hospital, Angers, France
- Hospital Universitario Puerta de Hierro Majadahonda (ES)
- Echosens (France) (FR)
- Corresponding author
- Kim, Seung Up
- Wong, Vincent Wai-Sun
- ORCID
- Lin, Huapeng
- Lee, Hye Won
- Yip, Terry Cheuk-Fung
- Tsochatzis, Emmanuel
- Petta, Salvatore
- Bugianesi, Elisabetta
- Yoneda, Masato
- Zheng, Ming-Hua
- Hagström, Hannes
- Boursier, Jérôme
- Goh, George Boon-Bee
- Chan, Wah-Kheong
- Sanyal, Arun J.
- Newsome, Philip N.
- Fan, Jian-Gao
- Castéra, Laurent
- Lai, Michelle
- Harrison, Stephen A.
- Wong, Grace Lai-Hung
- Pennisi, Grazia
- Armandi, Angelo
- Nakajima, Atsushi
- Liu, Wen-Yue
- Shang, Ying
- Llop, Elba
- Teh, Kevin Kim-Jun
- Asgharpour, Amon
- Kim, Seung Up
- Wong, Vincent Wai-Sun
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2024-04-16
- Volume
- 331
- Issue
- 15
- Pages
- 1287
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W4393037494
- Cited by
- 250
- References
- 32
- Citations by year
- 2026: 106 · 2025: 98 · 2024: 46
- FWCI
- 76.29
- Type
- journal article
- Language
- en
- Open access
- green
- pmc.ncbi.nlm.nih.gov
- Locations
- JAMA (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion, other-oa)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
- Funders
- Pfizer
- AstraZeneca
- Gilead Sciences
- Kowa Company
- Novo Nordisk
- Siemens Healthineers
- Japan Society for the Promotion of Science (21K08012)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver Disease and Transplantation
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Keywords
- vibration-controlled transient elastography, non-alcoholic fatty liver disease, liver-related events, liver fibrosis, liver cirrhosis, noninvasive fibrosis assessment, outcome prediction, hepatic decompensation, hepatocellular carcinoma, liver transplantation, controlled attenuation parameter, hepatic steatosis, natural history (disease)
- MeSH terms
- Adolescent, Adult, Esophageal and Gastric Varices, Fatty Liver, Female, Gastrointestinal Hemorrhage, Carcinoma, Hepatocellular, Humans, Liver, Liver Cirrhosis, Liver Neoplasms, Male, Middle Aged, Vibration, Cohort Studies, Elasticity Imaging Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
